
Shattuck Labs (STTK) Stock Forecast & Price Target
Shattuck Labs (STTK) Analyst Ratings
Bulls say
Shattuck Labs Inc is strategically positioned within the burgeoning market for inflammatory bowel disease (IBD), projected to reach $26.8 billion in sales by 2028, which suggests a favorable financial landscape for its product candidates. The company’s lead programs, including SL-325 and its half-life extended version SL-425, aim to leverage the significant insights related to the TL1A/DR3 signaling pathway, demonstrating improved therapeutic potential over existing treatments in preclinical studies. With a robust financial foundation evidenced by a cash runway extending into 2027, Shattuck Labs is well-equipped to advance its innovative therapeutic candidates in a promising market segment.
Bears say
Shattuck Labs Inc. faces significant challenges in its financial outlook due to the risk of failed or inconclusive clinical trials, which could severely restrict the company's ability to secure adequate funding necessary for drug development. The recent halt in development of SL-172154, coupled with the pivot towards an autoimmune-focused pipeline with early-stage assets, has created a lack of near-term value drivers, increasing uncertainty for investors. Additionally, the prevailing negative sentiment surrounding the CD47 space in oncology may further hinder the company's clinical progress and overall valuation.
This aggregate rating is based on analysts' research of Shattuck Labs and is not a guaranteed prediction by Public.com or investment advice.
Shattuck Labs (STTK) Analyst Forecast & Price Prediction
Start investing in Shattuck Labs (STTK)
Order type
Buy in
Order amount
Est. shares
0 shares